Who owns Neuphoria Therapeutics Inc.?
- Ticker: NEUP
- CUSIP Number: 64136e102
Tip: Access positions for across all investors
Analyze quarterly positions in Neuphoria Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Neuphoria Therapeutics stock
Who bought or sold Neuphoria Therapeutics Inc. this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Lynx1 Capital Management | 875k | $3.6M | 0% | Mar 2026 |
|
| AdvisorShares Investments | 155k | $632k | 16% | Mar 2026 |
|
| Shay Capital | 151k | $615k | 100% | Mar 2026 |
|
| Balyasny Asset Management | 142k | $579k | 100% | Mar 2026 |
|
| Squadron Capital Management | 77k | $312k | 100% | Mar 2026 |
|
| Geode Capital Management | 52k | $212k | 201% | Mar 2026 |
|
| Ikarian Capital | 47k | $193k | 0% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 34k | $137k | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 30k | $122k | 0% | Mar 2026 |
|
| FNY Investment Advisers | 27k | $115k | 0% | Jun 2026 |
|
| Citadel Advisors | 19k | $79k | 100% | Mar 2026 |
|
| Boothbay Fund Management | 14k | $57k | 0% | Mar 2026 |
|
| Virtu Financial | 12k | $49k | 100% | Mar 2026 |
|
| Commonwealth Equity Services | 11k | $46k | 0% | Mar 2026 |
|
| Merck & Co | 10k | $41k | 0% | Mar 2026 |
|
| UBS Group | 2.3k | $9.4k | 40% | Mar 2026 |
|
| Rhumbline Advisers | 202.00 | $821.998600 | 0% | Mar 2026 |
|
| Morgan Stanley | 58.00 | $232.000000 | 0% | Mar 2026 |
|
Who sold out of Neuphoria Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| None | Dec 2025 | 169k | $656k |
| Diadema Partners | Dec 2025 | 50k | $194k |
| Jane Street | Dec 2025 | 17k | $64k |
| Bridgeway Capital Management | Dec 2025 | 15k | $57k |
| Persistent Asset Partners | Dec 2025 | 13k | $52k |
| XTX Topco | Dec 2025 | 12k | $47k |
| Tower Research Capital | Dec 2025 | 1.4k | $5.4k |